SCYNEXIS pivots to rare kidney disease with $8M acquisition and $40M private placement
SCYNEXIS (NASDAQ:SCYX) announced a transformative strategic shift on Tuesday, March 31, 2026, transitioning its core focus toward rare kidney diseases through a significant asset acquisition and a major equity financing.










